CBAYのニュース
CymaBay Therapeutics Chief Financial Officer Awarded $3.24M Worth of Stock Options 2023/05/23 15:04:23 Benzinga
Harish Shantharam , Chief Financial Officer at CymaBay Therapeutics (NASDAQ: CBAY ), reported a large acquisition of company stock options on May 22, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Shantharam, Chief Financial Officer at CymaBay Therapeutics, a company in the Health Care sector, was just awarded stock options worth 360,000 shares of CBAY. The options give Shantharam the right to buy the company''s stock at $8.76 per share. CymaBay Therapeutics shares are trading up 2.68% at $8.99 at the time of this writing on Tuesday morning. Since the current price is $8.99, this makes Shantharam''s 360,000 … Full story available on Benzinga.com
Why CymaBay Therapeutics Stock Nose-Dived This Week 2023/05/19 21:59:16 The Motley Fool
Investors did not warmly greet the latest news from the biotech.
Gout Therapeutics Market to See Huge Demand by 2030: Regeneron Pharmaceuticals, CymaBay Therapeutics, LG Life Sciences 2023/05/18 16:30:55 EIN News Marijuana
Gout Therapeutics Market Current Status and Future Prospects PUNE, MAHARASHTRA, INDIA, May 18, 2023 /EINPresswire.com/ -- According to HTF Market Intelligence, the Global Gout Therapeutics market to witness a CAGR of 13.7% during forecast period …
CymaBay Therapeutics Inc. (NASDAQ: CBAY) Bullish Stock Forecast for 2023 with $19.00 Per Share 2023/05/16 17:30:00 Marketing Sentinel
In the latest trading session, 1.43 million CymaBay Therapeutics Inc. (NASDAQ:CBAY) shares changed hands as the company’s beta touched 0.27. With the company’s most recent per share price at $9.57 changed hands at -$0.83 or -7.93% at last look, the market valuation stands at $1.02B. CBAY’s current price is a discount, trading about -17.24% off … CymaBay Therapeutics Inc. (NASDAQ: CBAY) Bullish Stock Forecast for 2023 with $19.00 Per Share Read More »
CymaBay Therapeutics, Inc. (CBAY) Q1 2023 Earnings Call Transcript 2023/05/16 02:52:02 Seeking Alpha
CymaBay Therapeutics, Inc. (NASDAQ:NASDAQ:CBAY) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ETCompany ParticipantsPaul Quinlan - General CounselSujal Shah - President and Chief…
CymaBay Therapeutics (NASDAQ:CBAY) Hits New 52-Week High at $10.79 2023/04/30 07:28:26 The AM Reporter
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating)’s share price hit a new 52-week high on Friday . The stock traded as high as $10.79 and last traded at $10.79, with a volume of 383730 shares changing hands. The stock had previously closed at $10.30. Analyst Upgrades and Downgrades Several analysts have weighed in on CBAY […]
Four Potential Breakout Stocks For The Rest Of The Week 2023/04/19 12:58:13 Benzinga
In trading, there will always be elegance in simplicity. If your trading operation lacks a cadre of PhDs to crunch data like Renaissance Technologies or D.E. Shaw, simplicity will always trump excessive sophistication. The other bit of trading wisdom that should rarely be violated is “the trend is your friend.” Below, we take a look at four of the most significant bullish trends in the market right now. One important caveat with regard to these four stocks is that all of them are triggering very high RSI readings and could be due for sharp pullbacks as a result. Nevertheless, these stocks are making extremely powerful moves and there is a strong likelihood that the coming days could see an extension of price gains. Play these stocks with relatively tight stops and look for price to extend beyond your entry quickly in order to confirm continued strength and momentum. The screen used to identify these four names was stocks with a market cap above $300 million, recording new 52-week highs on above 200% average volume on Monday.
CymaBay Therapeutics Files Mixed Shelf 2023/03/23 20:53:04 Investing.com
https://www.investing.com/news/assorted/cymabay-therapeutics-files-mixed-shelf-432SI-3038495
CymaBay Therapeutics, Inc. (CBAY) Q4 2022 Earnings Call Transcript 2023/03/17 00:43:08 Seeking Alpha
CymaBay Therapeutics, Inc. (NASDAQ:NASDAQ:CBAY) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ETCompany ParticipantsPaul Quinlan - General CounselSujal Shah - Chief Executive…
CymaBay Therapeutics GAAP EPS of -$0.30 misses by $0.01 2023/03/16 20:08:47 Seeking Alpha
CymaBay Therapeutics press release (CBAY): Q4 GAAP EPS of -$0.30 misses by $0.01.Held $135.5 million in cash, cash equivalents and investments as of December 31, 2022.
CymaBay Therapeutics Inc. (CBAY) Q2 2022 Earnings Call Transcript 2022/08/12 08:30:53 The Motley Fool
CBAY earnings call for the period ending June 30, 2022.
Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2022 Results - Earnings Call Transcript 2022/08/12 03:16:06 Seeking Alpha
Cymabay Therapeutics, Inc. (NASDAQ:NASDAQ:CBAY) Q2 2022 Earnings Conference Call August 11, 2022, 16:30 ET Company Participants Paul Quinlan - General Counsel, Chief Compliance Officer…
CymaBay Therapeutics: Q2 Earnings Insights 2022/08/11 20:59:31 Benzinga
CymaBay Therapeutics (NASDAQ: CBAY ) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:06 PM. Here''s what investors need to know about the announcement. Earnings CymaBay Therapeutics missed estimated earnings by 3.33%, reporting … Full story available on Benzinga.com